Generic Flector Patch Availability
FLECTOR (diclofenac epolamine - patch;topical)
Manufacturer: INST BIOCHEM
Approval date: January 31, 2007
Strength(s): 1.3% [RLD]
Has a generic version of Flector Patch been approved?
No. There is currently no therapeutically equivalent version of Flector Patch available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Flector Patch. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
External anti-inflammatory and analgesic plaster preparation
Issued: March 4, 1997
Inventor(s): Akazawa; Mitsuji
Assignee(s): Teikoku Seiyaku Co., Ltd. Altergon S.A.
An external anti-inflammatory and analgesic plaster preparation includes as an active ingredient a salt of diclofenac, 2[(2,6-dichlorophenyl)amino]benzene-acetic acid, with a cyclic organic having the general formula (I): ##STR1## wherein X is a group of the formula --(CH.sub.2)m-- in which m is an integer of 0 or 1 and n is an integer of 2 and a pH value of the preparation is adjusted to a range of 7.3 to 9.0.Patent expiration dates:
- April 13, 2019✓
- April 13, 2019
More about Flector Patch (diclofenac topical)
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|